Sugammadex dosing challenges in pediatric neuromuscular reversal—Comments on Cates et al.

This article discusses a study on the dosing challenges of sugammadex in pediatric patients under 2 years of age. The study found that patients under 3 months of age and weighing less than 4.7 kg are at an increased risk of residual weakness and may require additional doses of sugammadex. However, the study lacked a standardized neuromuscular monitoring protocol, which may have affected the results. The authors suggest the need for a well-designed clinical trial to determine effective sugammadex doses for pediatric patients. [Extracted from the article]